公开(公告)号：EP3759142A1

公开(公告)日：2021-01-06

申请号：EP19710951.5

申请日：2019-03-01

Applicant: Five Prime Therapeutics, Inc.

Inventor： KAPLAN, Charles ,  PALUMBO, Alessandro ,  MILLER, Kathy ,  PARK, Hangil ,  MENDOZA, Nerissa ,  GHODDUSI, Majid

IPC: C07K16/28 ,  A61P37/00

公开(公告)号：EP3380523A1

公开(公告)日：2018-10-03

申请号：EP16816789.8

申请日：2016-11-22

Applicant: Five Prime Therapeutics, Inc.

Inventor： PIERCE, Kristen ,  POWERS, Janine ,  PALENCIA, Servando ,  SIKORSKI, Robert ,  GHODDUSI, Majid ,  KRISHNAN, Kartik

IPC: C07K16/28 ,  G01N33/574

CPC classification number: C07K16/2863 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/55 ,  C07K16/2818 ,  C07K16/2896 ,  C07K16/3015 ,  C07K16/3023 ,  C07K16/303 ,  C07K16/3038 ,  C07K16/3046 ,  C07K16/3069 ,  C07K16/3084 ,  C07K2317/34 ,  C07K2317/41 ,  G01N33/5091 ,  G01N33/57407 ,  G01N33/57446 ,  G01N33/57492 ,  G01N2333/71 ,  G01N2800/52

Abstract: Provided herein are uses of fibroblast growth factor receptor 2 (FGFR2) inhibitors in cancer treatment, in some cases in combination with immune stimulating agents, such as inhibitors of PD-1 or PD-L1. In some embodiments, FGFR2 inhibitors may comprise FGFR2 antibodies or FGFR2 extracellular domain (ECD) polypeptides, or FGFR2 ECD fusion molecules comprising an FGFR2 ECD and a fusion partner. In some embodiments, PD-1/PD-L1 inhibitors may comprise anti-PD-1 antibodies such as antibodies that bind to PD-1 or to PD-L1 and inhibit interactions between these proteins, as well as PD-1 fusion proteins or polypeptides.